World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
54121
World Ranking
18949
National Ranking
55

Overview

Carlos H. Barrios is affiliated with the Pontifical Catholic University of Rio Grande do Sul in Brazil. Their research primarily focuses on oncology and related medical fields, with a significant number of publications contributing to cancer research and treatment.

The main fields of study covered in their work include Medicine and Biochemistry, Genetics and Molecular Biology. Within these disciplines, the subfields of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Economics and Econometrics, and Genetics are notable areas of contribution.

The primary topics addressed in their research encompass:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer

Carlos H. Barrios has published extensively in various scientific venues, with frequent contributions to:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • ESMO Open

Frequent coauthors collaborating with Barrios include Sherene Loi, Hope S. Rugo, Nadia Harbeck, Javier Cortés, and Seock-Ah Im.

Significant recent papers include:

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial (2020, The Lancet)
  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2021, New England Journal of Medicine)
  • Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC (2020, New England Journal of Medicine)
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer (2021, Annals of Oncology)
  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial (2020, The Lancet)

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

    Ernst-Ruediger Kuse;Ploenchan Chetchotisakd;Clovis Arns da Cunha;Markus Ruhnke

  • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

    F. Saad;J. E. Brown;C. Van Poznak;T. Ibrahim

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

    Pasi A Jänne;Alice T Shaw;José Rodrigues Pereira;Gaëlle Jeannin

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Planning cancer control in Latin America and the Caribbean

    Paul E. Goss;Brittany L. Lee;Brittany L. Lee;Tanja Badovinac-Crnjevic;Kathrin Strasser-Weippl

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Evandro De Azambuja;Andrew P. Holmes;Martine Piccart-Gebhart;Eileen Holmes

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Hiroji Iwata
Hiroji Iwata Aichi Cancer Center
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Véronique Diéras
Véronique Diéras Institute Curie
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Miguel Martin
Miguel Martin Complutense University of Madrid
Sylvia Adams
Sylvia Adams New York University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open doors to rewarding healthcare careers, even if studying Medicine in the USA isn’t your chosen path. Many students pursue nursing programs for their flexibility, affordability, and strong job prospects.

For aspiring nurses, there are several routes available. If you are looking for cost-effective advanced degrees, the cheapest phd nursing programs offer opportunities to specialize further while minimizing student debt. Registered Nurses (RNs) interested in advancing may consider affordable rn to bsn programs, which are designed for working professionals who want to earn their bachelor’s remotely.

Non-nursing majors have quick entry options into the field through accredited online direct entry msn programs for non-nursing majors. These programs allow individuals from other backgrounds to transition into nursing leadership and advanced clinical roles.

If you are searching for accessible routes, the easiest bsn program to get into can simplify the admission process and help you quickly start your healthcare career, all from the flexibility of home.

Best Scientists Citing Carlos H. Barrios

Trending Scientists